US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Articles published by NanoViricides, Inc.

News headline image
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers NNVC
News headline image
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
From NanoViricides, Inc.
Via AccessWire
Tickers NNVC
News headline image
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
From NanoViricides, Inc.
Via AccessWire
Tickers NNVC
News headline image
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers NNVC
News headline image
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers NNVC
News headline image
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
From NanoViricides, Inc.
Via AccessWire
Tickers NNVC
News headline image
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
From NanoViricides, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers NNVC
News headline image
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
From NanoViricides, Inc.
Via AccessWire
Tickers NNVC
News headline image
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers NNVC